223 related articles for article (PubMed ID: 18067013)
1. Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes.
Kodali D; Mesa H; Rawal A; Cao Q; Gupta P
Leuk Lymphoma; 2007 Dec; 48(12):2375-80. PubMed ID: 18067013
[TBL] [Abstract][Full Text] [Related]
2. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals.
Cabello AI; Collado R; Ruiz MA; Martínez J; Navarro I; Ferrer R; Sosa AM; Carbonell F
Leuk Res; 2005 Apr; 29(4):365-70. PubMed ID: 15725469
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.
Terpos E; Verrou E; Banti A; Kaloutsi V; Lazaridou A; Zervas K
Leuk Res; 2007 Apr; 31(4):559-62. PubMed ID: 16820206
[TBL] [Abstract][Full Text] [Related]
4. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
5. Splenectomy in patients with mixed myelodysplastic/myeloproliferative disease.
Kraemer D; Rüdiger T; Reimer P; Müller-Hermelink HK; Wilhelm M
Ann Hematol; 2002 Jun; 81(6):308-11. PubMed ID: 12107559
[TBL] [Abstract][Full Text] [Related]
6. Marked thrombocytosis in a child with advanced myelodysplastic syndrome.
Claviez A; Ngoumou B; Harder L; Baumann I; Niemeyer C
Leuk Lymphoma; 2004 Apr; 45(4):849-50. PubMed ID: 15160971
[TBL] [Abstract][Full Text] [Related]
7. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
8. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous remission of anemia associated with a myelodysplastic syndrome with disease evolution into a myeloproliferative state.
Tefferi A; Inwards DJ; Hoyer JD
Acta Haematol; 1999 Mar; 101(1):50-2. PubMed ID: 10085439
[TBL] [Abstract][Full Text] [Related]
10. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
11. [Mixed myelodysplastic and myeloproliferative syndromes].
Neuwirtová R; Mociková K; Jelínek J; Musilová J; Havlícek F; Adamkov M; Michalová K; Cermák J; Jonásová A; Smolíková A; Straub J; Tothová E; Voglová J; Vozobulová V; Waltrová L
Cas Lek Cesk; 1997 Dec; 136(23):724-9. PubMed ID: 9476375
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders.
Occhipinti E; Correa H; Yu L; Craver R
Pediatr Blood Cancer; 2005 Mar; 44(3):240-4. PubMed ID: 15368549
[TBL] [Abstract][Full Text] [Related]
13. Sideroblastic anaemia with reactive thrombocytosis versus myelodysplastic/myeloproliferative disease.
Pérez Sánchez I; Pérez Corrala A; Menarguez Palanca J; Mayayo Crespo M; Escudero Soto A; Pintado Cros T
Leuk Lymphoma; 2003 Mar; 44(3):557-9. PubMed ID: 12688334
[TBL] [Abstract][Full Text] [Related]
14. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
[TBL] [Abstract][Full Text] [Related]
15. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
[TBL] [Abstract][Full Text] [Related]
16. Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.
Kern W; Bacher U; Schnittger S; Alpermann T; Haferlach C; Haferlach T
Cytometry B Clin Cytom; 2013 May; 84(3):194-7. PubMed ID: 23283847
[TBL] [Abstract][Full Text] [Related]
17. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
18. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.
Phekoo KJ; Richards MA; Møller H; Schey SA;
Haematologica; 2006 Oct; 91(10):1400-4. PubMed ID: 17018393
[TBL] [Abstract][Full Text] [Related]
19. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.
Gattermann N; Billiet J; Kronenwett R; Zipperer E; Germing U; Nollet F; Criel A; Selleslag D
Blood; 2007 Feb; 109(3):1334-5. PubMed ID: 17244688
[No Abstract] [Full Text] [Related]
20. Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders.
Steensma DP; Porcher JC; Hanson CA; Lathrop CL; Hoyer JD; Lasho TA; Tefferi A; Higgs DR
Br J Haematol; 2007 Nov; 139(3):439-42. PubMed ID: 17910635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]